Guggenheim Capital LLC Aerie Pharmaceuticals Inc Transaction History

Guggenheim Capital LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$6.37 - $15.23 $89,307 - $213,524	14,020 New	14,020 $212,000
Q2 2018 Aug 14, 2018	SELL	$47.85 - $70.45 $254,753 - $375,075	-5,324 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$51.15 - $61.0 $13,196 - $15,738	258 Added 5.09%	5,324 $289,000
Q4 2017 Feb 14, 2018	SELL	$50.85 - $65.1 $81,665 - $104,550	-1,606 Reduced 24.07%	5,066 $303,000
Q3 2017 Nov 14, 2017	BUY	$48.6 - $60.1 $324,259 - $400,987	6,672	6,672 $324,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Guggenheim Capital LLC with notifications on news.